Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection

Chen, Caifeng; Xia, Feng; Liao, Huiyu; Jin, Wenjing; Zhang, Jian; Wang, Yu; Gong, Lulu; Liu, Jingjun; Yuan, Xiaohui; Zhao, Bin-Bin; Zhang, Ding; Chen, Guofeng; Wan, Ying; Guo, Jian; Hu, Yan; He, You–Wen

doi:10.1038/srep06359

Cited by 40 publications

(34 citation statements)

References 37 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The roles of sICAM-1, PDGF-AB/BB, and TFF3 remain unclear in ACD; however, these proteins were shown to play immunomodulatory functions in other diseases [21,22,23]. Thus, the levels of CCL5, TFF3, sICAM-1, and PDGF-AB/BB might be exploited in monitoring the progression of ACD, and perhaps evaluating the effectiveness of treatment.…”

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers of Allergic Contact Dermatitis: A Pilot Study

Zinkevičienė

Kainov²,

Lastauskienė³

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Allergic contact dermatitis (ACD) is an inflammatory skin disease caused by repeated skin exposure to contact allergens. The goal of this pilot study was to identify inflammatory proteins which can serve as biomarkers for ACD. Methods: We measured levels of 102 cytokines, chemokines, and growth factors in the sera of 16 ACD patients during acute and remission phases, and 16 healthy volunteers. Results: Serumlevels of adiponectin, chemokine (C-C motif) ligand 5 (CCL5), C-reactive protein (CRP), chitinase 3-like 1 (CHI3L1), complement factor D (CFD), endoglin, lipocalin-2, osteopontin, retinol-binding protein 4 (RBP4), and platelet factor 4 (PF4) were significantly higher, whereas levels of trefoil factor 3 (TFF3) were significantly lower, in ACD patients than in healthy controls. In ACD patients, serum levels of CCL5 were elevated, whereas levels of TFF3, soluble intercellular adhesion molecule-1 (sICAM-1), and platelet-derived growth factor (PDGF)-AB/BB were found to be lower during the remission phase of the disease. Conclusions: Serum levels of adiponectin, CCL5, CRP, CHI3L1, CFD, endoglin, lipocalin-2, osteopontin, RBP4, PF4, and TFF3 might be exploited as biomarkers for ACD, whereas levels of CCL5, TFF3, sICAM-1, and PDGF-AB/BB might be exploited for evaluation of disease progression and efficacy of ACD treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers of Allergic Contact Dermatitis: A Pilot Study

Zinkevičienė

Kainov²,

Lastauskienė³

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Besides its function in transcriptional control, we and others have shown that JMJD6 also interacts with multiple splicing factors, and is involved in gene splicing control (Heim et al, 2014, Webby et al, Liu et al, 2013, Rahman et al, 2011, Yi et al, 2017). JMJD6 has been implicated in a multitude of biological processes, including embryonic development (Bose et al, 2004, Li et al, 2003, Kunisaki et al, 2004), cell cycle control (Wang et al, 2014a), cellular proliferation and motility (Lee et al, 2012, Chen et al, 2014), adipocyte differentiation (Hu et al, 2015) and development of various types of cancers, such as breast (Poulard et al, 2015, Lee et al, 2012, Aprelikova et al, 2016), lung (Zhang et al, 2013) and colon cancer (Wang et al, 2014a). …”

Section: Introductionmentioning

confidence: 99%

JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex

et al. 2018

View full text Add to dashboard Cite

SUMMARY Whereas the actions of enhancers in gene transcriptional regulation are well established, roles of JmjC domain-containing proteins in mediating enhancer activation remain poorly understood. Here we report that recruitment of the JmjC domain-containing protein 6 (JMJD6) to estrogen receptor alpha (ERα)-bound active enhancers is required for RNA polymerase II recruitment and enhancer RNA production on enhancers, resulting in transcriptional pause release of cognate estrogen target genes. JMJD6 was found to interact with MED12 in the mediator complex to regulate its recruitment. Unexpectedly, JMJD6 is necessary for MED12 to interact with CARM1, which methylates MED12 at multiple arginine sites and regulates its chromatin binding. Consistent with its role in transcriptional activation, JMJD6 is required for estrogen/ERα-induced breast cancer cell growth and tumorigenesis. Our data have uncovered a critical regulator of estrogen/ERα-induced enhancer, coding gene activation and breast cancer cell potency, providing a potential therapeutic target of ER-positive breast cancers.

show abstract

“…Many studies have reported that the angiogenic cytokine PDGF-BB is associated with the prognosis and severity of several diseases of the liver such as hepatocellular carcinoma, liver brosis, and chronic viral hepatitis. Besides, a previous report indicated that serum levels of PDGF-BB are signi cantly correlated with the degree of liver damage and brosis in chronic hepatitis B (CHB) patients [18]. Additionally, serum PDGF-BB levels have been suggested to decrease with increased brosis, indicating that the depleted serum PDGF-BB is a potential biomarker for assessing the brosis stage in patients with CHB [19].…”

Section: Discussionmentioning

confidence: 99%

Serum Platelet-derived Growth Factor-BB Levels as a Potential Biomarker in Assessing the Metabolic Activity of Lesions in Alveolar Echinococcosis Patients

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract ObjectiveAlveolar echinococcosis (AE) is a chronic disease caused by the larval stage of Echinococcus multilocularis. Assessing the metabolic activity of AE lesions is critical to evaluate disease progression and survey treatment options. There is an urgent need to identify more rapid, convenient, and non-invasive clinical detection methods to substitute the current techniques. Herein, we evaluated the viability of platelet-derived growth factor-B B (PDGF-BB) as a biomarker for detecting the metabolic activity of AE patients. Concentration of serum PDGF-BB homodimers (sPDGF-BB) was assessed via ELISA. Correlations of PDGF-BB expression levels with clinicopathological features of AE patients were analyzed using SPSS. ResultsThe concentrations of sPDGF-BB were significantly lower in AE patients (p<0.0001), particularly in HMAE patients (p<0.05). The expression levels of PDGF-BB were significantly higher in CLT in AE patients (p<0.0001). We found that metabolically active AE and sPDGF-BB are significantly negatively correlated (r=-0.624, p=0.0004). Besides, the local expression levels of PGFD-BB was positively correlated with metabolic activity, the PNM stage, and lesion size. Notably, the sPDGF-BB levels were proposed as a potential biomarker for assessing metabolic activity of AE, with 85.7% sensitivity and 81% specificity (95% confidence interval, P = 0.003).

show abstract

Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection

Cited by 40 publications

References 37 publications

Serum Biomarkers of Allergic Contact Dermatitis: A Pilot Study

Serum Biomarkers of Allergic Contact Dermatitis: A Pilot Study

JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex

Serum Platelet-derived Growth Factor-BB Levels as a Potential Biomarker in Assessing the Metabolic Activity of Lesions in Alveolar Echinococcosis Patients

Contact Info

Product

Resources

About